A review of 11 studies suggests endometriosis may take a cumulative toll on work, but long-term data are scarce.
With the approval, there's a rival to perioperative pembrolizumab with enfortumab vedotin for patients with cisplatin-ineligible muscle-invasive bladder cancer.
Dapagliflozin may improve ascites control in patients with cirrhosis and refractory ascites and reduce the need for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results